evaluating landmark clinical data for her2-low breast cancer
Published 5 months ago • 5 plays • Length 11:30Download video MP4
Download video MP3
Similar videos
-
14:00
evaluating a treatment for her2-positive metastatic breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
54:43
the science of her2-low breast cancer and implications for the pathology team
-
5:16
treatment options for her2-low breast cancer: all you need to know
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
2:21
adcs for the treatment of her2-low breast cancer
-
11:12
her2-low breast cancer: destiny or good science?
-
0:52
defining her2-low breast cancer as a clinical subtype
-
20:34
latest update on her2-low breast cancer and implications for clinical practice
-
31:59
assessing risk in hormone receptor-positive/her2-negative early breast cancer: how to approach ch...
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
1:26
genomic and transcriptomic landscape of her2-low breast cancer
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
1:43
dr hamilton on implications of destiny-breast06 on the her2-low breast cancer paradigm
-
1:53
her2 assessment in breast cancer
-
6:51
adcs for her2 and her2-low breast cancer